Medifast Analyst Ratings
Medifast Analyst Ratings
While ratings are subjective and will change, the latest Medifast (MED) rating was a maintained with a price target of $75.00 to $93.00. The current price Medifast (MED) is trading at is $103.57, which is out of the analyst's predicted range.| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 07/31/2023 | -10.21% | DA Davidson | $75 → $93 | Maintains | Neutral |
| 05/02/2023 | -31.45% | DA Davidson | $94 → $71 | Maintains | Neutral |
| 02/22/2023 | -9.24% | DA Davidson | $106 → $94 | Maintains | Neutral |
| 11/04/2022 | 2.35% | DA Davidson | $278 → $106 | Downgrades | Buy → Neutral |
| 08/04/2022 | 168.42% | DA Davidson | $352 → $278 | Maintains | Buy |
| 08/04/2022 | 44.83% | Jefferies | $345 → $150 | Downgrades | Buy → Hold |
| 06/02/2022 | 239.87% | DA Davidson | $341 → $352 | Maintains | Buy |
| 02/24/2022 | 229.25% | DA Davidson | $349 → $341 | Maintains | Buy |
| 11/08/2021 | 236.97% | DA Davidson | $395 → $349 | Maintains | Buy |
| 05/05/2021 | 281.38% | DA Davidson | $302 → $395 | Maintains | Buy |
| 02/26/2021 | 191.59% | DA Davidson | $239 → $302 | Maintains | Buy |
| 01/25/2021 | 155.87% | Jefferies | $205 → $265 | Upgrades | Hold → Buy |
| 01/12/2021 | 130.76% | DA Davidson | $205 → $239 | Maintains | Buy |
| 11/05/2020 | 97.93% | DA Davidson | $180 → $205 | Upgrades | Neutral → Buy |
| 06/25/2020 | 58.35% | B. Riley Securities | → $164 | Initiates Coverage On | → Buy |
| 05/06/2020 | -16.96% | DA Davidson | $83 → $86 | Maintains | Neutral |
| 02/27/2020 | -19.86% | DA Davidson | $74 → $83 | Maintains | Neutral |
| 11/08/2019 | -28.55% | DA Davidson | $250 → $74 | Downgrades | Buy → Neutral |
| 07/25/2019 | 25.52% | Jefferies | → $130 | Initiates Coverage On | → Buy |
| 02/27/2019 | 108.55% | Sidoti & Co. | $211 → $216 | Maintains | Buy |
| 11/08/2018 | — | Sidoti & Co. | Upgrades | Neutral → Buy |
| 日期 | 上行/下行 | 分析公司 | 目标价格变动 | 评级变动 | 之前/当前的评级 |
|---|---|---|---|---|---|
| 07/31/2023 | -10.21% | DA Davidson | 75 美元 → 93 美元 | 维护 | 中立 |
| 05/02/2023 | -31.45% | DA Davidson | 94 美元 → 71 美元 | 维护 | 中立 |
| 02/22/2023 | -9.24% | DA Davidson | 106 美元 → 94 美元 | 维护 | 中立 |
| 2022 年 4 月 11 日 | 2.35% | DA Davidson | 278 美元 → 106 美元 | 降级 | 买入 → 中性 |
| 08/04/2022 | 168.42% | DA Davidson | 352 美元 → 278 美元 | 维护 | 购买 |
| 08/04/2022 | 44.83% | 杰富瑞 | 345 美元 → 150 美元 | 降级 | 买入 → 持有 |
| 06/02/2022 | 239.87% | DA Davidson | 341 美元 → 352 美元 | 维护 | 购买 |
| 2022 年 2 月 24 日 | 229.25% | DA Davidson | 349 美元 → 341 美元 | 维护 | 购买 |
| 2021 年 8 月 11 日 | 236.97% | DA Davidson | 395 美元 → 349 美元 | 维护 | 购买 |
| 2021 年 5 月 5 日 | 281.38% | DA Davidson | 302 美元 → 395 美元 | 维护 | 购买 |
| 2021 年 2 月 26 日 | 191.59% | DA Davidson | 239 美元 → 302 美元 | 维护 | 购买 |
| 2021 年 1 月 25 日 | 155.87% | 杰富瑞 | 205 美元 → 265 美元 | 升级 | 持有 → 买入 |
| 2021 年 12 月 1 日 | 130.76% | DA Davidson | 205 美元 → 239 美元 | 维护 | 购买 |
| 2020 年 5 月 11 日 | 97.93% | DA Davidson | 180 美元 → 205 美元 | 升级 | 中性 → 买入 |
| 06/25/2020 | 58.35% | B. 莱利证券 | → 164 美元 | 启动覆盖开启 | → 购买 |
| 2020 年 6 月 5 日 | -16.96% | DA Davidson | 83 美元 → 86 美元 | 维护 | 中立 |
| 02/27/2020 | -19.86% | DA Davidson | 74 美元 → 83 美元 | 维护 | 中立 |
| 11/08/2019 | -28.55% | DA Davidson | 250 美元 → 74 美元 | 降级 | 买入 → 中性 |
| 2019 年 7 月 25 日 | 25.52% | 杰富瑞 | → 130 美元 | 启动覆盖开启 | → 购买 |
| 02/27/2019 | 108.55% | Sidoti & Co. | 211 美元 → 216 美元 | 维护 | 购买 |
| 11/08/2018 | — | Sidoti & Co. | 升级 | 中性 → 买入 |
What is the target price for Medifast (MED)?
Medifast (MED) 的目标价格是多少？
The latest price target for Medifast (NYSE: MED) was reported by DA Davidson on July 31, 2023. The analyst firm set a price target for $93.00 expecting MED to fall to within 12 months (a possible -10.21% downside). 6 analyst firms have reported ratings in the last year.
DA Davidson于2023年7月31日公布了Medifast（纽约证券交易所代码：MED）的最新目标股价。这家分析公司将目标股价定为93.00美元，预计MED将在12个月内跌至12个月内（可能下跌-10.21％）。去年有6家分析公司公布了评级。
What is the most recent analyst rating for Medifast (MED)?
分析师对Medifast（MED）的最新评级是多少？
The latest analyst rating for Medifast (NYSE: MED) was provided by DA Davidson, and Medifast maintained their neutral rating.
Medifast（纽约证券交易所代码：MED）的最新分析师评级由DA Davidson提供，Medifast维持中性评级。
When is the next analyst rating going to be posted or updated for Medifast (MED)?
Medifast (MED) 的下一个分析师评级何时公布或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Medifast, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Medifast was filed on July 31, 2023 so you should expect the next rating to be made available sometime around July 31, 2024.
分析师在进行了广泛的研究（包括浏览公开财务报表、与Medifast的高管和客户交谈以及听取财报电话会议）后得出了股票评级。大多数分析师每三个月进行一次评级，因此每家公司每年应该获得4个评级。Medifast的最后一次评级是在2023年7月31日提交的，因此您应该预计下一个评级将在2024年7月31日左右公布。
Is the Analyst Rating Medifast (MED) correct?
分析师对Medifast (MED) 的评级正确吗？
While ratings are subjective and will change, the latest Medifast (MED) rating was a maintained with a price target of $75.00 to $93.00. The current price Medifast (MED) is trading at is $103.57, which is out of the analyst's predicted range.
尽管评级是主观的，将会发生变化，但最新的Medifast（MED）评级维持不变，目标股价为75.00美元至93.00美元。Medifast（MED）目前的交易价格为103.57美元，超出了分析师的预测区间。
